A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma
Plain-language summary
This trial is testing Microdevices for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome at various stages of their disease. Patients are randomly assigned to different treatment groups. The study looks at both safety and how well the treatment controls the lymphoma. This trial is available at 1 location in the United States. The trial is currently recruiting patients.
Who can join (key eligibility)
- Age 18 Years or older
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Microdevices (DEVICE): The microdevice was developed as a tool with the ultimate goal to help screen several existing and investigational drugs directly within a patient's tumor to identify what drugs are the most effective for treating a patient's cancer. | Standard of care therapy (OTHER): Participant to receive standard of care therapy as previously determined by participant's treating oncologist and/or dermatologist, which may include a skin-directed or systemic therapy | Standard of care systemic therapy (OTHER): Participant to receive standard of care therapy as previously determined by participant's treating oncologist and/or dermatologist, which must include a systemic therapy.
Microdevices, Standard of care therapy, Standard of care systemic therapy
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details